13 May 2025 in Nature Communications
Manual interpretation of CT images for bone metastasis (BM) detection in primary cancer remains challenging. We present an automated Bone Lesion Detection System (BLDS) developed using CT scans from 2518 patients (9177 BMs; 12,824 non-BM lesions) across five hospitals. The system, developed on 1271 patients and tested on 1247 multicenter cases, demonstrates 89.1% lesion-wise sensitivity (1.40 false-positives/case [FPPC]) in detecting bone lesions on non-contrast CT scans, with 92.3% and 91.1% accuracy in classifying BM/non-BM lesions for internal and external test sets, respectively. Outperforming radiologists in lesion detection (40.5% sensitivity; 0.65 FPPC), BLDS shows lower BM detection sensitivity than junior radiologists, though comparable to trainees. BLDS improves radiologists’ lesion-wise sensitivity by 22.2% in BM detection and reduces reading time by 26.4%, while maintaining 90.2% patient-wise sensitivity and 98.2% negative predictive value in real-world validation (n = 54,610). The system demonstrates significant potential to enhance CT-based BM interpretation, particularly benefiting trainees.
8 January 2026 in Clinical Cancer Research
Purpose: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT). Patients and Methods: In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. Results: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05). Conclusions: PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs. See related commentary by Dossa et al., p. 2127